37
Participants
Start Date
November 30, 2005
Primary Completion Date
October 31, 2017
Study Completion Date
October 31, 2017
Targretin® (bexarotene)
pegylated liposomal doxorubicin hydrochloride
NYU Cancer Institute at New York University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Hackensack University Medical Center Cancer Center, Hackensack
Roswell Park Cancer Institute, Buffalo
M. D. Anderson Cancer Center at University of Texas, Houston
National Cancer Institute (NCI)
NIH
Tibotec Pharmaceutical Limited
INDUSTRY
M.D. Anderson Cancer Center
OTHER
NYU Langone Health
OTHER
Hackensack Meridian Health
OTHER
Roswell Park Cancer Institute
OTHER
Memorial Sloan Kettering Cancer Center
OTHER